Dr. Geng received her Ph.D. degree from Tokyo University, Japan. She is currently a professor and principle investigator of Shanghai Institute of Materia Medica, Chinese Academy of Sciences，and serves as the Academic Director General. Dr. Geng’s research is focused on the innovative drug discovery and development to promote conceptual and clinical breakthroughs in disease areas with huge unmet medical needs, such as Alzheimer’s disease (AD) and cancer. She has played a leading role in the development of the first-in-class anti-AD treatment GV-971, conditional approved in China in 2019 and got formal approval in 2020 from the US Food and Drug Administration (FDA) for its international multi-center Phase III clinical study in the U.S. She has also led the development of over ten targeted anticancer therapies, including seven undergoing clinical trials in China. In parallel to anticancer drug discovery, her team is engaged in biomarker discovery to guide personalized cancer therapy and mechanism-based combination therapies. Dr. Geng has published more than 255 research articles in peer-review journals including Cell, Cancer Cell, Cell Res, J Natl Cancer Inst, Nat Commun, Hepatology, Cancer Res etc. She is the co-inventor of more than 200 domestic or international patents. Dr. Geng is the receipt of a number of prestigious national awards including China Guanghua Engineering Science and Technology Award, Ho Leung Ho Lee Prize for Scientific & Technological Progress, WuJieping-Paul Janssen Medical & Pharmaceutical Award.